(PDF) Prolonged-Release Fampridine Treatment Improved

Prolonged-Release Fampridine Treatment Improved Subject-Reported Impact of Multiple Sclerosis: Item-Level Analysis of the MSIS-29

Journal of the Neurological Sciences - Netherlands

doi 10.1016/j.jns.2016.08.052

Full Text

Abstract

Available in full text

Categories

Date

November 1, 2016

Authors

Claudio Gasperini

Raymond Hupperts

Christine Short

Publisher

Elsevier BV

Related search

Pnd139 - Impact of Prolonged-Release Fampridine on Fatigue Among People With Multiple Sclerosis in a Multi-Country Study

Value in Health

Occupational Health

English

Prm197 - Responder Definition of the Multiple Sclerosis Impact Scale (Msis)-29 V2 Among Patients With Secondary Progressive Multiple Sclerosis

Value in Health

Occupational Health

English

PND5 Budget Impact of Oral Prolonged-Release Fampridine for Management of Walking Disability Associated With Multiple Sclerosis in Taiwan

Value in Health

Occupational Health

English

Pnd144 - Reported Quality of Life in People With Multiple Sclerosis Under Long Term Treatment With Fampridine

Value in Health

Occupational Health

English

Budget Impact Analysis of Delayed-Release Dimethylfumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy

Value in Health

Occupational Health

English

Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, MSWS-12, Abilhand-56 and Sf-36

Value in Health

Occupational Health

English

Prm9 - A Longitudinal, Item-Level Analysis Methodology to Support the Interpretability of Multi-Item Patient-Reported Outcomes

Value in Health

Occupational Health

English

Walking, Quality of Life, and Safety With Prolonged-Release Fampridine Treatment in Clinical Practice: Interim Results of the Liberate Study

Journal of the Neurological Sciences

English

The Changing Multiple Sclerosis Treatment Landscape: Impact of New Drugs and Treatment Recommendations

European Journal of Clinical Pharmacology

English